It has been recommended that in patients with compromised renal function (i.e. 30< eGFR <60 and 30<eGFR<45 mL/ min/1.73 m 2 ) and those with normal renal function and other co-morbidities, either withholding or continuing of metformin prior to iodinated contrast medium exposure should be based on patient's medical condition. Lactic acidosis (LA) secondary to metformin administration is a rare incident with a very high mortality rate (≥50%). Hypoxia has been suggested to contribute to metformin-associated lactic acidosis (MALA) in 90% of patients developing this condition. In susceptible patients such as those with renal insufficiency, the level of plasma metformin is increased particularly after exposure to iodinated contrast media (ICM). One major concern in patients with renal insufficiency is to adjust the metformin dose based on the renal functional capacity prior to ICM examination. In this review, we assessed metformin tolerable threshold in diabetic patients with renal failure. We also reviewed metformin withdrawal criteria in patients with chronic kidney disease (CKD) exposed to intravenous ICM during angiography. Our results indicated that in patients with insufficient renal function (i.e. 30< estimated glomerular filtration rate(eGFR) <60 and 30<eGFR<45 mL/min/1.73 m 2 ), or those with acceptable renal function (eGFR ≥60 mL/ min/1.73 m 2 ) and concomitant comorbidities, the decision to withhold or reinitiate metformin should be based on patient's medical condition.
Introduction
Lactic acidosis (LA) is a marker of inadequate tissue perfusion and oxygen supply. Insufficient oxygen delivery triggers anaerobic metabolism which finally transforms pyruvate to lactate (1) . Metformin-associated lactic acidosis (MALA) is a relatively rare incident; however, the condition renders a very high mortality rate (2) . Evidences from comprehensive meta-analyses and clinical studies have specified the efficiency and safety of metformin in appropriate dose. On the other hand, even elevated serum concentration of metformin alone is rarely indicated as a trigger for LA. Actually, in more than 90% of patients with MALA, the condition has been associated with a hypoxic circumstance that can prompt LA (3, 4) . MALA is generally preventable in most outpatient individuals. In fact, dose adjustment strategies can be effectively implemented to avoid MALA in patients with kidney failure, hepatic insufficiency, severe hypoxia, chronic heart failure, shock (e.g. surgery) and those who abused alcohol (5) . Nevertheless, in vulnerable individuals with predisposing conditions (i.e. metformin overdose, lactate level >5 mM or large anion gap), severe academia (blood pH < 7.4), and low serum bicarbonate level (<22 mM)), MALA may be triggered following metformin accumulation in the body (6) .
The accumulation of metformin alone can explain the development of LA in only ≤10% of cases who mostly are also identified with either metformin overdose or acute kidney injury. The MALA is considered as the LA developed following metformin administration in patients with no obvious other predisposing and related diseases (7) .
Hypoxia is a serious predisposing factor and a prognostic indicator for MALA. Diabetes and diabetic nephropathy (8) , renal failure (9, 10) , and intravascular iodinated contrast media (ICM) (11) decrease medullary oxygenation predisposing medullary region to hypoxia. Actually, the intensity of hypoxia; and not the lactate or metformin concentrations, predicts the mortality rate in patients, and therefore metformin administration must be reconsidered in the presence of tissue hypoxia (12) . Although a recent study has clarified no association between metformin administration and LA; however, this indication may not be applicable to susceptible individuals with metformin overdose (13) .
Reduced kidney function and metformin clearance are the most significant risk factors of MALA. In this regard, diabetic patients are at risk of LA following metformin administration. Other risk factors of MALA include reduced tissue oxygenation (such as in heart failure, hypoxemia, ICM exposure, sepsis and shock), as well as disturbed lactate metabolism (such as in alcoholism, or liver fibrosis) ( Table 1 ) (5). Therefore, it is highly recommended to avoid metformin administration in these contraindicated conditions.
Materials and Methods
For this review, we used a variety of sources including PubMed, Web of Science, Embase, EBSCO, Google Scholar and Scopus. The search was conducted, using combinations of the following key words and or their equivalents; iodinated contrast media, lactic acidosis, metformin, chronic kidney disease, metforminassociated lactic acidosis, hypoxemia, acute kidney injury, contrast induced nephropathy, percutaneous coronary intervention, nephrotoxicity and glomerular filtration rate.
Contrast induced nephropathy
Radiology imaging techniques such as angiography and computed tomography angiography (CT-angiography) usually provide evidence about the structure of blood vessels and body organs assisting in the diagnosis and treatment of various diseases. In most of these techniques, ICMs which are renal toxic agents and may cause complications in patients with renal disease are administered. In patients with pre-existing renal damage, particularly diabetic individuals, using ICMs in radiographic procedures may lead to contrast-induced nephropathy (CIN). CIN is defined as the elevation of serum creatinine ≥ 25% of the standard level within 48 hours. ICMs may promote their nephrotoxic effects either indirectly by induction of renal hypoxia through hemodynamic alterations such as inducing renal vasoconstriction, and reducing vasodilatation, kidney blood supply, blood pressure and glomerular filtration rate or directly by cytotoxic effects against renal tubular and endothelial cells (11, 14) . As kidneys receive almost 20% of cardiac output, they are particularly sensitive to hypoxia. Decreased kidney oxygenation, particularly renal medulla hypoxia, is an indicator of CIN. Applying ICM also increases the viscosity of kidney arterioles that are the main sources of renal medulla blood supply, which further exaggerating medullary hypoxia. These agents can also worsen, the endothelial dysfunction by inducing toxic effects toward endothelial and other renal cells (15) .
Metformin-associated lactic acidosis following ICM induced nephropathy
By reducing kidney function, ICMs increase the risk of metformin accumulation predisposing to LA. Because of the presumed association between ICM and the risk of LA in patients using metformin, the present recommendations restrict the administration of metformin in patients exposing to such agents, such as those referred for percutaneous coronary intervention (PCI) (16) . Nonetheless, the incidence of nephrotoxicity after ICM exposure is very low in individuals with normal serum creatinine level and renal function (17, 18) . The risk of MALA after ICM exposure is particularly escalated in simultaneous presence of other contraindications of metformin usage, particularly renal insufficiency (19) . In accordance, multiple studies on diabetic patients treated with metformin have indicated that the risk of CIN is minimal in diabetic patients without renal disorder (3, 16) . Overall, metformin avoidance to prevent LA in patients who are subjected to intravenous ICM may be only restricted to those with abnormal renal function.
Metformin administration in patients with chronic kidney disease
There has been a point of contrary to either administer lowdose metformin in patients with partial renal impairment (20) or withdraw the drug in patients with advanced chronic kidney disease (CKD) (21, 22) . There have been recommendations to eliminate the renal functional limitations on metformin administration. On the other hand, there have been many cases of severe side effects and unfavorable complications related to metformin (23) . In fact, it has been argued that the restricting guidelines have likely saved thousands of lives each year from LA, hypoglycemia, and pancreatitis (6) .
The estimated glomerular filtration rate (eGFR) which is reported as mL/min/1.73 m 2 is calculated based on serum creatinine, weight, height, age, and/or gender (24) . The eGFR has been a better indicator respective to serum creatinine for predicting renal insufficiency. In a cohort study on more than 50.000 patients with type 2 diabetes, the predictability of different eGFRs has been assessed on the safety of metformin administration (25) . The study showed, the risk of LA was ~13-fold higher in patients with reduced renal function treated with >2 g/d metformin in comparison with patients with no history of metformin exposure. The risk of either LA or elevated lactate concentration boosted in patients with severe renal failure (30≤eGFR <60 mL/min/1.73 m 2 ) with the risk being highly escalated in patients received prolonged metformin therapy.
In patients without renal problems, metformin improves glucose and lipid metabolisms, helps to lose weight, and finally postpones diabetes development. It has been argued that contradicting metformin administration in CKD patients may deprive millions of diabetic patients from the beneficial effects of this therapeutic agent. Clinical practice guidelines have suggested the thresholds of kidney failure and low GFR for protecting CKD patients from potential metformin adverse effects. Drug administration organizations and expert associations in various countries have also suggested metformin cut off limits to be applied in CKD patients.
The ) or normal kidney function, the drug withdrawal must be decided considering the patients' medical history. Because of the risk of CIN, monitoring serum-creatinine level seems necessary in all patients. While there has been no established relationship between metformin administration and either intravascular ICM exposure or nephrotoxicity, nevertheless, interactions between metformin, ICM and LA may be a hazardous combination leading to renal damage. The risk of metformin accumulation and LA is exaggerated in patients with CIN. The prevalence of CIN has been reported in the range of 0.1% to 13% with preexisting renal damage being an independent risk factor for this condition (30) . One major point of concern in patients undergoing ICM has been the level of renal function in which metformin should be stopped or restarted. Table 3 presents different guidelines on metformin administration during ICM in diabetic patients.
Based on the statements presented in Tables 2 and 3 , the followings can be guidelines concluded; • Some guidelines (such as ACR, CAR and RANZCR)
have not regarded the eGFR≤30 mL/min/1.73 m 2 as an absolute contraindication for metformin discontinuation before ICM exposure and suggested that the drug should be only stopped immediately prior to the exposure (31).
• In patients with CKD, some guidelines have recommended that metformin should be stopped at 
45-60
Continue and monitor renal function three times per year
30-45
Reduced dose to almost half of primary dose, check renal function check four times per year <30 Contraindicated, stop metformin administration any eGFR before intravenous ICM administration (6) .
On the other hand, in patients with compromised renal function (i.e. either 30<eGFR<60 or 30<eGFR<45 mL/min/1.73 m 2 ) and those with normal kidney function and other co-morbidities, the decision on withholding and reinitiating metformin prior or at the time of exposure should be based on the patient's medical condition (32) .
• It appears to be safe to continue metformin in patients with normal renal function (i.e. eGFR >60 mL/min/1.73 m 2 ) with no other comorbidities.
• The, g-I/eGFR <1.42 formula is an easy and helpful indicator for establishing the safe iodinated contrast medium-dose based on the exposure eGFR values. Moreover, g-I/eGFR might have a close relationship with the development of nephropathy requiring dialysis as well as contrast-induced nephropathy (33).
• Other techniques such as magnetic resonance imaging, using iso-or low osmolar ICM agents at the minimum effective dose, and finally applying optimal hydration and other strategies to avoid CIN should be considered in at-risk patients. The commonly conventional practice for radiologists is to stop metformin administration 24 to 48 hours before administration of contrast media in individuals with an eGFR of below 60 mL/min/1.73 m 2 and to renew its administration after testing kidney function 48 hours subsequent the radiography (34). ) and those with normal renal function and other comorbidities, either withholding or continuing of metformin prior to ICM exposure should be based on patient's medical condition.
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